Cited by 78Endometriosis Research and TreatmentReproductive Health and ContraceptionEctopic Pregnancy Diagnosis and Management

Safety of medical treatments for endometriosis

Berlanda, Nicola, Somigliana, Edgardo, Viganò, Paola, Vercellini, Paolo·2016·Expert Opinion on Drug Safety

Abstract

INTRODUCTION: All medical treatments for endometriosis are equally effective in relieving pain. However, all of them alleviate pain symptoms for as long as they are used, but pain always relapses when medication is discontinued. Therefore, medications need to be used in the long term. AREAS COVERED: Formulations of estro-progestins that contain less than 50 µg of estrogen are associated with a low risk of venous thrombosis, myocardial infarction and stroke. When considering the neoplastic effects, data suggest that the overall risk of invasive cancer by age 60 is not increased in previous users of hormonal contraceptives. The use of progestins for contraception has never been associated with an increased risk of breast cancer, venous thromboembolism or bone fractures. Although more data on long-term therapy with progestins are needed, treatment of endometriosis with progestins may be feasible in women with metabolic or cardiovascular contraindications to estroprogestin. The other medications for the treatment of pain associated with endometriosis are less appropriate for long term administration because of side effects (danazol and GnRH analogues), costs (aromatase inhibitors and GnRH agonists) or necessity of complex regimens of associations (GnRH agonists and add back therapy or aromatase inhibitors plus progestins). EXPERT OPINION: Progestins and estroprogestins are safe drugs to use in the long term. Adherence to these medications may be high because, being a contraceptive, they are perceived less as a medication for the treatment of a disease. The annual cost of therapy compares favorably with other available medications. Progestins and estroprogestins represent the first-line medications for the treatment of endometriosis associated pain.

Integrity signals

Registry

Crossref · 10.1517/14740338.2016.1121991

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

1 of the 76 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Berlanda, N., Somigliana, E., Viganò, P., & Vercellini, P.
Affiliations
  • University of Milan (IT)
  • Vita-Salute San Raffaele University (IT)
Corresponding author
Berlanda, Nicola
Venue
Expert Opinion on Drug Safety
Published
2015-12-10
Volume
15
Issue
1
Pages
21-30
ISSN
  • 1474-0338 (ISSN-L)
  • 1744-764X
OpenAlex
W2204624009
Cited by
78
References
76
Citations by year
2026: 6 · 2025: 6 · 2024: 13 · 2023: 4 · 2022: 9 · 2021: 5 · 2020: 2 · 2019: 3 · 2018: 10 · 2017: 13 · 2016: 7
FWCI
1.52
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Drug Safety (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ectopic Pregnancy Diagnosis and Management
Keywords
endometriosis, progestins, estroprogestins, long-term hormonal therapy, venous thromboembolism, breast cancer risk, cardiovascular risk, danazol, GnRH agonist, aromatase inhibitors, add-back therapy, pain management, medication adherence, treatment costs
MeSH terms
Drug Combinations, Endometriosis, Ethinyl Estradiol, Female, Humans, Middle Aged, Norpregnenes, Progestins, Recurrence, Time Factors, Pelvic Pain, Medication Adherence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review